Product Description
ÊA long-acting pegylated form of a recombinant therapeutic agent which is chemically identical to or similar to an endogenous human granulocyte colony-stimulating factor (G-CSF). Produced endogenously by monocytes, fibroblasts, and endothelial cells, G-CSF binds to and activates specific cell surface receptors, stimulating neutrophil progenitor proliferation and differentiation and selected neutrophil functions. Conjugation of the cytokine with a branched polyethylene glycol molecule (pegylation) significantly increases its therapeutic half-life. (NCI04) (Sourced from: https://thesaurus.cancer.gov/ncitbrowser/pages/concept_details.jsf?dictionary=NCI_Thesaurus&version=21.03e&code=C1854&ns=ncit&type=all&key=null&b=1&n=0&vse=null)
Mechanisms of Action: G-CSF Agonist
Novel Mechanism: Yes
Modality: Coagulation Factor
Route of Administration: Subcutaneous
FDA Designation: *
Approval Status: Not Approved
Approved Countries: None
Approved Indications: None
Known Adverse Events: None
Company: Pfizer
Company Location: NEW YORK NY 10017
Company CEO: Albert Bourla
Additional Commercial Interests: None
Clinical Description
Countries in Clinic:
Active Clinical Trial Count:
Recent & Upcoming Milestones
Highest Development Phases
Phase 2: Febrile Neutropenia|Breast Cancer|Endodermal Sinus Tumor|Embryonal Carcinoma|Germinoma|Mixed Tumor, Malignant|Choriocarcinoma|Teratoma
Phase 1: Neutropenia
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
Latest Trial Update Date |
Data Updated |
|---|---|---|---|---|---|---|---|
| ACTRN12615001049561 | N/A |
Completed |
Neutropenia |
2015-11-13 |
2024-08-29 |
Treatments |
|
| ZIN-130-1505 | P1 |
Completed |
Neutropenia |
2016-06-01 |
2019-03-20 |
Treatments |
|
| ACNS2021 | P2 |
Recruiting |
Mixed Tumor, Malignant|Embryonal Carcinoma|Choriocarcinoma|Endodermal Sinus Tumor|Teratoma|Germinoma |
2029-12-21 |
2024-11-27 |
Primary Endpoints |
|
| 2015-002057-35 | P2 |
Completed |
Febrile Neutropenia |
2017-10-05 |
2022-03-13 |
Treatments |
|
| ZIN-130-1504 | P2 |
Completed |
Breast Cancer |
2017-10-01 |
2019-03-20 |